Study
| Multicenter, randomized, open-label trial |
| Stage 3 or 4 advanced Hodgkin’s lymphoma |
| A+AVD (n:664) or ABVD (n:670) |
Efficacy
| OS favored A+AVD over ABVD (HR: 0.59; P=0.009) |
| 6 year OS: 93.9% (95% CI, 91.6 to 95.5) vs 89.4% (95% CI, 86.6 to 91.7) |
| 6 year PFS: 82.3% and 74.5%, HR:0.68; 95% CI, 0.53 to 0.86) |
Safety
| Completed all treatment: 89.3% vs 90.7% |
| Any cause related death: 39 vs 64 patients |
| Hodgkin Lymphoma related death: 32 vs 45 patients |
| Second cancer related death: 1 vs 11 patients |
N Engl J Med 2022; 387:310-320
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
http://doi.org/10.1056/NEJMoa2206125
Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022
